Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06889493 · ClinicalTrials.gov registry record · Phase 1

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

A Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma, sponsored by Peter Hosein, MD.

Recruiting
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT06889493 is a Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma that is actively recruiting participants, run by Peter Hosein, MD. The registered enrollment target is 36 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06889493, a Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma, is actively recruiting participants, sponsored by Peter Hosein, MD.

RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.

Conditions Studied

Neuroendocrine Tumors Neuroendocrine Carcinoma

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab
  • BIOLOGICAL Seneca Valley Virus-001 (SVV-001)

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2025-05-19
Est. Completion 2030-06-01
Phase Phase 1

Sponsor

Peter Hosein, MD

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06889493

The ClinicalTrials.gov registry entry for NCT06889493 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (80% lower). The listed sponsor is Peter Hosein, MD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT06889493 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06889493 about?

NCT06889493 is a clinical study titled "SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)". The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3. The highest dose...

What is the current status of trial NCT06889493?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-05-19. Estimated completion is 2030-06-01.

What conditions does trial NCT06889493 study?

This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma.

What interventions are being tested in trial NCT06889493?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Seneca Valley Virus-001 (SVV-001) (BIOLOGICAL).

Who is sponsoring clinical trial NCT06889493?

This trial is sponsored by Peter Hosein, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06889493 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroendocrine Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuroendocrine Tumors

All registered trials for this condition

Neuroendocrine Carcinoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.